CDMO SK Pharmteco has announced plans to invest $260 million in a new small molecule and peptide facility in Sejong, South Korea, the fifth in its home country and the cornerstone of its global manufacturing network. This is scheduled to begin operations in late 2026, creating over 300 jobs.

Following launch at a symposium in Boston in September, Ampac Fine Chemicals (AFC), an SK Pharmteco company, has announced the development of a new series of skid-based modules for continuous flow processes. These, it claims, will revolutionise the technique, closing the gap between benchtop development with microreactors and manufacturing scale.

SK Pharmteco has announced a two-phase, $35 million investment to boost both capacity and capabilities at its SK Biotek subsidiary’s manufacturing plant at Swords, Dublin. This is due online in 2024, the campus’s 60th anniversary as a small molecule API manufacture, and will lead to a 50% total increase in capacity.